Insider · CIK 0001760682
Dashyant Dhanak
Files at INCY (INCYTE CORP), DCPH (Deciphera Pharmaceuticals, Inc.). First filing Jan 30, 2023, latest Jan 30, 2023.
In brief
Dashyant Dhanak files SEC Form 4 as officer at INCY (INCYTE CORP), and also at DCPH (Deciphera Pharmaceuticals, Inc.). Since Jan 30, 2023, Dashyant Dhanak has reported 0 open-market buys worth $0 and 1 open-market sell worth $206k, the latest filed on Jan 30, 2023.
A track record needs three past buys with six months of prices behind them; Dashyant Dhanak has 0, so none is measured yet.
The newest scored trade: sold $206k of INCY on Jan 26, 2023, filed Jan 30, 2023, scored 22 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
INCY: INCYTE CORP
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | INCYTE CORP | $206k 2,419 shares | -4% | +30% from low0% from high |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +25,913 | - | - | 184,088 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -184,088 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,900 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -69,100 | - | - | 0 | Jun 11, 2024 |
| Feb 15, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +17,275 | $0.00 | $0 | 158,175 | Feb 20, 2024 |
| Feb 15, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +69,100 | $0.00 | $0 | 69,100 | Feb 20, 2024 |
| Feb 16, 2023 | INCY INCYTE CORP | MOption exercise Common Stock | +3,693 | $65.42 | $242k | 56,956 | Feb 21, 2023 |
| Feb 16, 2023 | INCY INCYTE CORP | MOption exercise Incentive Stock Option (right to buy)derivative | -3,693 | $0.00 | $0 | 0 | Feb 21, 2023 |
| Jan 26, 2023 | INCY INCYTE CORP | SOpen-market sale Common Stock10b5-1 | -2,419 | $85.00 | $206k | 53,263 | Jan 30, 2023 |
| Jan 20, 2023 | INCY INCYTE CORP | AGrant or award Common Stock | +4,980 | $0.00 | $0 | 55,682 | Jan 24, 2023 |
| Jan 20, 2023 | INCY INCYTE CORP | AGrant or award Employee Stock Option (right to buy)derivative | +16,128 | $0.00 | $0 | 16,128 | Jan 24, 2023 |
| Dec 12, 2022 | INCY INCYTE CORP | FTax withholding Common Stock | -533 | $82.36 | $44k | 50,702 | Dec 13, 2022 |
Questions about Dashyant Dhanak
Answered from the filings on this page, as of the latest one.
Is Dashyant Dhanak buying or selling?
Not in the last 12 months. Dashyant Dhanak's latest open-market trade on SEC Form 4 was sold $206k of INCY on Jan 26, 2023.
How did Dashyant Dhanak's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dashyant Dhanak has 0.
Where does Dashyant Dhanak file Form 4?
Dashyant Dhanak has filed Form 4 at INCY (INCYTE CORP) as EVP & Chief Scientific Officer; DCPH (Deciphera Pharmaceuticals, Inc.) as EVP & Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.